ArticleMedicine2026
Association between body roundness index and serum 25-hydroxyvitamin D in women with and without breast cancer: A cross-sectional analysis of NHANES 2001-2018.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Breast cancer (BC) is the most prevalent tumor in women, ranking first in incidence and mortality in many countries. Previous studies have suggested that. Body Roundness Index (BRI) is positively correlated with BC risk and negatively correlated with serum vitamin D levels. But few well-designed studies have explored the full impact of BC status on the relationship between BRI and serum vitamin D. So we aimed to evaluate the relationship between BRI and serum 25-hydroxy vitamin D in women without or with BC. We used data from the National Health and Nutrition Examination Survey to explore the association between BRI and serum 25-hydroxy vitamin D in women without or with BC. By stratifying participants according to BC status, we further assessed the difference between BRI and serum 25-hydroxy vitamin D levels in participants with and without BC using multivariate Linear regression (interaction test). A total of 21,774 participants were enrolled, comprising 21,212 non-BC patients and 562 BC patients. After adjusting for covariates, the association of BRI with serum 25-hydroxy vitamin D appeared to differ between non-BC group and BC group (β: -1.82, 95% confidence interval: -1.98~-1.66 vs β:-0.48,95%Cl: -1.67~0.71). Furthermore, when BRI was converted to a categorical variable, there was evidence of interaction between BC status and BRI in decreasing the levels of serum 25-hydroxy vitamin D (P-value for interaction = .030). In non-BC patients, A nonlinear relationship was found between BRI and serum 25-hydroxy vitamin D, which had a threshold around 7.38; in BC patients, the relationship between BRI and serum vitamin D was not significant (P = .434). Sensitivity analyses using propensity score matching yielded directionally consistent results, although the categorical interaction was no longer statistically significant. Our findings suggest a differential cross-sectional association between BRI and serum 25-hydroxyvitamin D in women with and without BC, which warrants confirmation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.